Supporting you so you can support your patients. The Galleri test only requires a simple blood draw, allowing integration into existing patient touchpoints such as annual health checks or routine blood work. Learn more about how we can help: https://bit.ly/3uQmwDO See Important Safety Information at https://bit.ly/45FRUlI #MCED #MultiCancerEarlyDetection #CancerScreening #DetectCancerEarly The Galleri test should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Galleri Test’s Post
More Relevant Posts
-
#artfunplus biomarkers are revolutionizing the landscape of #healthcare with their myriad of possible #ClinicalApplications. From primary to secondary #prevention, the possibilities are vast and promising. 🚀 👉 Consider this: in cases of premature coronary artery disease, Artfun+ #biomarkers offer a beacon of hope by predicting the recurrence of #ischemicevents. 💔 This foresight enables doctors to intervene early, potentially #savinglives and improving #PatientOutcomes. 💯 Learn more: https://lnkd.in/dvgTEvDi The implications extend to critical scenarios such as #predicting the risk of #aorticruptures in patients. Armed with this predictive power, physicians can make informed decisions on when to preemptively operate, thus mitigating the risk of life-threatening complications. 🏥 #ArtfunBiomarkers #MedicalInnovation #HealthcareAdvancements
-
-
A Rare Disease is one that affects a very small percent of the population. Those living with a rare disease face challenges such as the lack of research, and difficulties in accessing care. At Terumo Blood and Cell Technologies, we are committed to advocating these patients’ needs and improving access to care. Did you know that therapeutic plasma exchanges (TPEs) are used for patients with over 187 diseases and indications, including many that are rare or orphan?* However, in the U.S. today, most of the therapeutic apheresis procedures are done in hospitals. Even though it can be safely deployed in settings outside the hospital -- somewhere more accessible for patients. We are more than just a medical device manufacturer. Every day, we are working with multiple stakeholders to make our technology more accessible to those in need. This #RareDiseaseDay, let’s take time to raise awareness of the importance of addressing these health inequalities. Here is a recent example about our effort to drive patient access: https://bit.ly/3FGtH3C * https://lnkd.in/g63tsnGM #RareDisease #AccessToCare #SCD #SickleCellDisease
-
-
Prioritize your health with the Galleri® Test - your proactive defense against multiple types of cancers. Want to find out if you're a good match? Click the 🔗 below and take our quick questionnaire! https://bit.ly/4cWcDFS #DirectPrimaryCare #Healthcare #GalleriTest #ConciergeMedicine #PreventativeHealth
-
-
The age-related macular degeneration (AMD) disease - anti-VEGF market, categorized by AMD types (dry and wet), exhibits diverse growth across end-users such as hospitals, specialty clinics, #ambulatorysurgicalcenters, and #homehealthcare. This market thrives on tailored treatments, innovative therapies, and expanding research, collectively addressing the varied needs of patients and transforming the landscape of AMD care. To know more, visit: https://lnkd.in/dsyTVa8y #DBMR #AMDInsights #MacularDegeneration #AntiVEGFTherapies #VisionHealth #AMDResearch #EyeCareInnovation #WetAMD #DryAMD #VisionPreservation #AMDAdvancements #Ophthalmology #EyeHealthMatters #InnovativeMedicine #AMDHope #RetinaCare #DBMRInsights
-
Equitable Access to care for rare diseases needs awareness and renewed thinking on solution deployment and entire patient pathway consideration in care program design
A Rare Disease is one that affects a very small percent of the population. Those living with a rare disease face challenges such as the lack of research, and difficulties in accessing care. At Terumo Blood and Cell Technologies, we are committed to advocating these patients’ needs and improving access to care. Did you know that therapeutic plasma exchanges (TPEs) are used for patients with over 187 diseases and indications, including many that are rare or orphan?* However, in the U.S. today, most of the therapeutic apheresis procedures are done in hospitals. Even though it can be safely deployed in settings outside the hospital -- somewhere more accessible for patients. We are more than just a medical device manufacturer. Every day, we are working with multiple stakeholders to make our technology more accessible to those in need. This #RareDiseaseDay, let’s take time to raise awareness of the importance of addressing these health inequalities. Here is a recent example about our effort to drive patient access: https://bit.ly/3FGtH3C * https://lnkd.in/g63tsnGM #RareDisease #AccessToCare #SCD #SickleCellDisease
-
-
Treating #BloodCancer requires an individualized approach that includes complementary and combinable therapies. We’re committed to developing innovative treatment options to help unlock transformational outcomes for patients by collaborating with the healthcare community, including patients. We’re dedicated to advancing our collective understanding of these diseases. That’s why at #ASH23 we are presenting new data from our differentiated portfolio, to help address the needs across multiple myeloma and B-cell malignancies. https://bit.ly/46ZnISI #MultipleMyeloma
-
VIDA's AI-driven mucus plug analysis will be featured in 5 #ATS2024 abstracts. In this analysis of #SARP patients by Peterson et al., a regional association between mucus plugging and downstream air trapping was evident in subjects with severe plugs. These results add to the growing evidence that plugs could be targeted with therapies to improve downstream air trapping in patients with asthma. https://hubs.ly/Q02wxnyz0 Meet with VIDA at ATS: https://hubs.ly/Q02wxrxs0 #mucusplugs #mucusplugging #asthma #digitalbiomarkers
-
-
Join us in San Diego for The Conference Board’s annual Employee Healthcare Conference to see how the Galleri multi-cancer early detection test can transform your employee healthcare programs. Register now: https://bit.ly/3TgkV3K The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests. See Important Safety Information: http://bit.ly/33m8pFa #EmployeeHealth #MCED #MultiCancerEarlyDetection
-
-
The ELSO (The Extracorporeal Life Support Organization) recently posted: Use of less intensive #anticoagulation in #ECMO could reduce bleeding complications and improve outcomes in #ARDS patients. A personalized approach should consider the underlying disease process 🩸 https://ow.ly/ycOp50Qz4My 👉 Authors’ reply: https://ow.ly/QH9Y50Qz4Mz 👉 The discussion refers to these findings from the #PROTECMO study on anticoagulation modalities and bleeding events in adults with #VVECMO: https://ow.ly/z6bm50Qz4MC Original #ELSO post: https://ow.ly/ee9I50Qz4MA
-
Even if there is a lack of compelling evidence from RCTs surrounding mortality due to some study design criteria like sample size and subgroup, this does not necessarily mean that there is no clinical benefit in the use of blood purification techniques in patients with sepsis. Some design methods such as introducing diagnostics may offer greater clarity in terms of the efficacy of these treatments. Please follow the link for more details: https://lnkd.in/g5xBQeeK #RCTs #sepsis #diagnostics
-
